Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Roivant Sciences (ROIV) emphasized positive registrational data for brepo in dermatomyositis (DM), positioning it as the first novel targeted therapy for the condition with a focused, capital-efficient launch strategy and IP through 2039, significantly de-risking its development for non-infectious uveitis (NIU) and cutaneous sarcoidosis. The company also outlined its strategy for RVN-1402 in Graves' disease, targeting a large, prevalent patient population, and expects key data for RVN-1401 in Thyroid Eye Disease (TED) and its sGC program in PH-ILD next year. On the legal front, Roivant anticipates a summary judgment ruling on Section 1498 applicability in its Moderna LNP litigation, potentially affecting over half of claimed damages, and noted favorable claim construction rulings in its Pfizer case, indicating significant near-term catalysts and strategic positioning.

Analysis

Roivant Sciences is strategically positioned following positive registrational data for its JAK1/TYK2 inhibitor, brepocitinib, in dermatomyositis (DM). The company's CEO highlights this as the first successful novel targeted therapy in a field characterized by prior development failures, offering a one-pill, once-a-day alternative to cumbersome IVIg regimens and high-dose steroids for a target population of 35,000 to 40,000 treated patients. The commercialization strategy appears capital-efficient, focusing on building relationships with approximately 200 key referral centers and leveraging a robust patient support organization, a model validated by Horizon's success. With patent protection through 2039, the DM data is presented as a significant de-risking event for brepocitinib's expansion into other indications like non-infectious uveitis (NIU), with data expected in H1 2027. Beyond brepo, the FcRn franchise presents substantial opportunities, particularly in Graves' disease, where the company targets a prevalent population of approximately 330,000 patients who are uncontrolled on existing therapies. Significant near-term catalysts exist outside the clinical pipeline, most notably in the LNP litigation. A pending summary judgment on the Section 1498 defense in the Moderna case could determine the applicability of government contractor immunity to nearly half of the $5 billion in damages sought by Roivant. Concurrently, favorable claim construction rulings have been secured in the separate Pfizer case, where the 1498 defense has not been asserted, strengthening Roivant's legal position.

Key Decisions for Investors

• Investors should monitor the execution of the capital-efficient commercial launch for brepocitinib in dermatomyositis, focusing on physician adoption within the 200 key referral centers and the effectiveness of the patient support program.
• The upcoming summary judgment ruling on the Section 1498 defense in the Moderna LNP litigation is a critical near-term catalyst that could significantly clarify the potential multi-billion dollar damages and should be watched closely.
• Evaluate the progress of the FcRn franchise, specifically the Graves' disease program targeting a large market, and the upcoming data for batoclimab in Thyroid Eye Disease (TED), which will be a key indicator of its competitive potential against incumbents like argenx.
• Consider the differentiated risk profile across Roivant's portfolio, weighing the de-risked commercial opportunity of brepocitinib against the higher-risk, high-reward pipeline assets like the rheumatoid arthritis program and the binary outcomes of the LNP litigation.